NCT02464228 · MORE INFO

Limitations, agreements, and source contact

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy · Source last updated 2024-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: There are agreements in place between clinical trial sites and the Sponsor (or its agents) that govern discussion or publication of trial results by the sites or their employees after the trial is completed.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: KO-TIP-002@kuraoncology.com
organization: Kura Oncology, Inc.
phone: +1 617-588-3755
title: Clinical Operations

Complete source fields

certain Agreement

other Details: There are agreements in place between clinical trial sites and the Sponsor (or its agents) that govern discussion or publication of trial results by the sites or their employees after the trial is completed.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

email: KO-TIP-002@kuraoncology.com
organization: Kura Oncology, Inc.
phone: +1 617-588-3755
title: Clinical Operations

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice